Orally ‐Delivered, Cytokine‐Engineered Extracellular Vesicles for Targeted Treatment of Inflammatory Bowel Disease
A nested delivery system for oral delivery of the anti-inflammatory cytokine IL-10 for the treatment of inflammatory bowel disease is developed. The new method for orally taking protein has high patient compliance, compared with intravenous or intramuscular administration routes. This proof-of-concept for IBD treatment also affords a versatile methodology for other oral pr otein-based therapeutics delivery. AbstractThe use of orally-administered therapeutic proteins for treatment of inflammatory bowel disease (IBD) has been limited due to the harsh gastrointestinal environment and low bioavailability that affects delivery to diseased sites. Here, a nested delivery system, termed Gal-IL10-EVs (C/A) that protects interleukin 10 (IL-10) from degradation in the stomach and enables targeted delivery of IL-10 to inflammatory macrophages infiltrating the colonic lamina propria, is reported. Extracellular vesicles (EVs) carrying IL-10 are designed to be secreted from genetically engineered mammalian cells by a plasmid system, and EVs are subsequently modified with galactose, endowing the targeted IL-10 delivery to inflammatory macrophages. Chitosan/alginate (C/A) hydrogel coating on Gal-IL10-EVs enables protection from harsh conditions in the gastrointestinal tract and favorable delivery to the colonic lumen, where the C/A hydrogel coating is removed at the diseased sites. Gal-IL10-EVs control the production of reactive oxygen species (ROS) and inhibit the expression of proinflamma...
Source: Small - Category: Nanotechnology Authors: Jingang Liu,
He Ren,
Chen Zhang,
Jiexin Li,
Qian Qiu,
Nan Zhang,
Ning Jiang,
Jonathan F. Lovell,
Yumiao Zhang Tags: Research Article Source Type: research
More News: Environmental Health | Gastroenterology | Genetics | Inflammatory Bowel Disease | Nanotechnology